Evolent Health (EVH) Reports In-Line Q4 EPS; Offers Guidance

Evolent Health (NYSE: EVH) reported Q4 EPS of $0.10, in-line with the analyst estimate of $0.10. Revenue for the quarter came in at $382.43 million versus the consensus estimate of $372.93 million.

GUIDANCE:

Evolent Health sees Q1 2023 revenue of $420-440 million, versus the consensus of $410.1 million.

Evolent Health sees FY2023 revenue of $1.92-1.96 billion, versus the consensus of $1.882 billion.

For earnings history and earnings-related data on Evolent Health (EVH) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• XP Inc. (XP) Tops Q2 EPS by 8c
• XP Inc eyes US banking license as next business step